- Home
- PED vs YARW Comparison
PED vs YARW Comparison
Compare PED & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PED | YARW |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.0M | 154.5M |
| IPO Year | 2012 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PED | YARW |
|---|---|---|
| Price | $15.27 | $17.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | 20.6K | ★ 130.6K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,751,000.00 | N/A |
| Revenue This Year | $212.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.67 | N/A |
| 52 Week Low | $8.64 | $18.05 |
| 52 Week High | $18.89 | $44.28 |
Technical Indicators
Market Signals| Indicator | PED | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 61.10 | 33.92 |
| Support Level | $11.38 | N/A |
| Resistance Level | $16.70 | $20.49 |
| Average True Range (ATR) | 0.72 | 1.54 |
| MACD | 0.21 | 0.36 |
| Stochastic Oscillator | 73.57 | 28.78 |
Price Performance
Historical ComparisonAbout PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.